Being a neurologist, my vision is to contribute to discovery, development and clinical implementation of novel therapies for neurological disorders. As such, I perform clinical trials and also have a preclinical research group.

The overarching goal of our research is to modify disease progression. We are especially interested in pericytes, guardians of the homeostasis of the brain’s microenvironment. We hypothesize that pericytes form the link between neurodegeneration, inflammation and vascular dysfunction. Microvascular alterations, blood-brain barrier leakage and pericyte dysfunction also play a crucial role in other, more acute brain pathologies, such as stroke and glioblastoma. Our lab has the mission to decode and modulate the language of pericytes in these different brain pathologies.

As a GCP-trained clinician with considerable experience in clinical studies, I also have a focus on novel clinical studies aiming not just at therapeutic improvement but structural regeneration. I have been investigator in several growth factor trials in Parkinson’s disease, a neurotransplantation trial addressing dopaminergic cells from fetal tissues (Transeuro) and I am clinical PI of the ongoing STEM-PD trial, a First-in-Human trial assessing the safety and tolerability of dopaminergic progenitor cells derived from human embryonic stem cells in Parkinson’s disease. 

I am also regularly teaching health care professionals e.g. as part of educations ogranized by the Swedish Parkinson Academy, or other specialized national and international teaching courses.